BNC105 Compound Targets Leukemia Progenitor Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML) are not curative due to resistance from early leukemia progenitor cells, leading to relapse in most patients, and are particularly ineffective for elderly patients, with a high percentage suffering from treatment-related deaths and relapse.
Innovation Solution
The use of a compound of formula (I), specifically 2-Methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran, or its salt, solvate, or prodrug, which selectively induces apoptosis in AML cells, potentially combined with other therapies, to achieve complete remission and eliminate residual disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy (daunorubicin and cytarabine) is used for AML treatment, then complete remission can be achieved in 60%-70% of patients, but treatment-related deaths occur in an unacceptably high percentage of elderly patients and relapse occurs in the majority of patients within 5 years
Solution Approach 1:
The patent extracts and eliminates early leukemia progenitor cells (ELPCs) specifically, which are the root cause of relapse and treatment resistance. By targeting ELPCs directly through the compound of formula (I), the treatment removes the source of disease recurrence while sparing normal hematopoietic stem cells, thereby reducing treatment-related deaths and relapse rates without compromising remission achievement
Solution Approach 2:
The compound of formula (I) acts as an intermediary agent that selectively targets ELPCs through a specific mechanism involving inhibition of ELPC-specific pathways. This intermediary compound bridges the gap between conventional chemotherapy and curative treatment by adding ELPC elimination capability while maintaining compatibility with standard induction and consolidation therapies
2Reliability
If high doses of chemotherapy are administered to eliminate residual disease, then consolidation therapy can achieve cure, but elderly patients over 70 years old cannot tolerate the current therapy and suffer from treatment-related deaths
Solution Approach 1:
The patent applies local quality by making the treatment selectively toxic only to ELPCs while being benign to normal cells. The compound of formula (I) exhibits localized action specifically at the ELPC level through selective binding to ELPC-specific targets, allowing effective elimination of residual disease without the systemic toxicity that limits chemotherapy dosing in elderly patients
Solution Approach 2:
The invention changes the fundamental parameter of treatment selectivity by introducing a compound with ELPC-specific activity. This parameter change enables the use of effective anti-ELPC doses without the conventional chemotherapy toxicity profile, as the compound's selective mechanism decouples efficacy from general cytotoxicity, allowing elderly patients to receive curative treatment
3Reliability
If targeted therapies (enasidenib, Midostaurin, Gemtuzumab ozogamicin) are used to specifically treat AML, then survival can be prolonged in specific patient subgroups, but these therapies may not work in other leukemia patients and are not universally effective
Solution Approach 1:
The patent achieves universality by developing a compound of formula (I) that targets a fundamental property of all AML cells (ELPCs) rather than relying on specific mutations or markers. The compound acts on conserved ELPC-specific pathways present across all AML subtypes, making it universally effective for AML patients regardless of their specific genetic profile or disease subtype
Solution Approach 2:
The invention segments the AML treatment approach by first eliminating ELPCs specifically with the compound of formula (I), then allowing standard consolidation therapy to complete remission. This segmentation separates the ELPC elimination function from general chemotherapy, enabling each component to be optimized independently and combined for universal AML treatment efficacy
Data Source
AI summary
The present invention relates to a method for the treatment of acute myeloid leukemia (AML) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of the presently-described formula (I) or a salt, solvate or prodrug thereof. Specific compounds of the invention include 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran which is also known as BNC105 and disodium 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate which is also known as BNC105P.